Affiliation: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
- A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomesMiia Turpeinen
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Drug Metab Dispos 37:1017-24. 2009..Taken together, these studies indicate that the formation of the active metabolite of nabumetone, 6-MNA, is predominantly catalyzed by CYP1A2 in HLMs with only minor contribution of other P450s...
- Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformationUlrich M Zanger
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
Anal Bioanal Chem 392:1093-108. 2008..In this review, we provide an up-to-date summary of the functional polymorphisms and aspects of the functional genomics of the major human drug-metabolizing cytochrome P450s, as well as their clinical significance...
- Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidationAna M Gomes
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Auerbachstrasse 112, 70376 Stuttgart, Germany
Pharmacogenomics 10:579-99. 2009..We investigated genetic and nongenetic POR variability and its impact on drug-oxidation activities in human liver microsomes...
- Pathway-Targeted Pharmacogenomics of CYP1A2 in Human LiverKathrin Klein
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tuebingen Stuttgart, Germany
Front Pharmacol 1:129. 2010..In conclusion, we identified novel trans-associations between regulatory genes and hepatic CYP1A2 function and expression, but additional genetic factors must be assumed to explain the full extent of CYP1A2 heritability...